Treating Alzheimer's disease with monoclonal antibodies: Current status and outlook for the future

Alzheimer's Research and Therapy

Volumn 5, Issue 6, 2013, Pages

  Prins, Niels D ^a   Scheltens, Philip ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AAB 003; AMYLOID BETA PROTEIN; BAN 2401; BAN2401; BAPINEUZUMAB; BART; BIIB 037; BIIB037; COMPLEMENT; CRENEZUMAB; DONEPEZIL; GALANTAMINE; GANTENERUMAB; GSK 933776; HUMAN MONOCLONAL ANTIBODY; MEMANTINE; PLACEBO; RIVASTIGMINE; SAR 228810; SAR228810; SOLANEZUMAB; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; AMYLOID RELATED IMAGING ABNORMALITY; COMPLEMENT ACTIVATION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INFLAMMATION; MENTAL DETERIORATION; MICROGLIA; MULTICENTER STUDY (TOPIC); MULTIPLE DRUG DOSE; PALLIATIVE THERAPY; PASSIVE IMMUNIZATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; VASOGENIC EDEMA;

EID: 84887973227     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt220     Document Type: Review

References (39)

1. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE, Clin Interv Aging 2008 3 211 225 18686744 (Pubitemid 352037861)
2. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H, BMJ 2005 331 321 327 10.1136/bmj.331.7512. 321 16081444
3. Disease modifying drugs targeting β-amyloid. Ozudogru SN, Lippa CF, Am J Alzheimers Dis Other Demen 2012 27 296 300 10.1177/1533317512452034 22815077
4. Alzheimer Disease: mechanistic understanding predicts novel therapies. Selkoe DJ, Ann Internal Med 2004 140 627 638 10.7326/0003-4819-140-8-200404200- 00010
5. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. Hardy J, J Neurochem 2009 110 1129 1134 10.1111/j.1471-4159.2009.06181.x 19457065
6. Preventing β-amyloid fibrillization and deposition: β-sheet breakers and pathological chaperone inhibitors. Wisniewski T, Sadowski M, BMC Neurosci 2008 9 Suppl 2 5 10.1186/1471-2202-9-S2-S5 19091002
7. Immunotherapy for Alzheimer's disease. Morgan D, J Intern Med 2011 269 54 63 10.1111/j.1365-2796.2010.02315.x 21158978
8. Which are the antibodies to watch in 2013? Reichert JM, MAbs 2013 5 1 4 10.4161/mabs.22976 23254906
9. Passive anti-amyloid immunotherapy in Alzheimer's disease: what are the most promising targets? Moreth J, Mavoungou C, Schindowski K, Immun Ageing 2013 10 18 10.1186/1742-4933-10-18 23663286
10. Vaccines: chasing the dream. Schnabel J, Nature 2011 475 18 S19 10.1038/475S18a 21760578
11. A beta oligomers-a decade of discovery. Walsh DM, Selkoe DJ, J Neurochem 2007 101 1172 1184 10.1111/j.1471-4159.2006.04426.x 17286590 (Pubitemid 46718812)
12. Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior. Selkoe DJ, Behav Brain Res 2008 192 106 113 10.1016/j.bbr.2008.02.016 18359102
13. Amyloid: little proteins, big clues. Schnabel J, Nature 2011 475 12 S14 10.1038/475S12a 21760575
14. The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes. Benilova I, Karran E, De Strooper B, Nat Neurosci 2012 15 349 357 10.1038/nn.3028 22286176
15. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T, Nat Med 2000 6 916 919 10.1038/78682 10932230 (Pubitemid 30644751)
16. Passive immunization against pyroglutamate-3 amyloid-β reduces plaque burden in Alzheimer-like transgenic mice: a pilot study. Frost JL, Liu B, Kleinschmidt M, Schilling S, Demuth HU, Lemere CA, Neurodegener Dis 2012 10 265 270 10.1159/000335913 22343072
17. Antibody 9D5 recognizes oligomeric pyroglutamate amyloid-β in a fraction of amyloid-β deposits in Alzheimer's disease without cross-reactivity with other protein aggregates. Venkataramani V, Wirths O, Budka H, Härtig W, Kovacs GG, Bayer TA, J Alzheimers Dis 2012 29 361 371 22232007
18. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Sperling RA, Jack CR, Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, Thies W, Bednar MM, Black RS, Brashear HR, Grundman M, Siemers ER, Feldman HH, Schindler RJ, Alzheimers Dement 2011 7 367 385 10.1016/j.jalz.2011.05.2351 21784348
19. An MRI rating scale for amyloid-related imaging abnormalities with edema or effusion. Barkhof F, Daams M, Scheltens P, Brashear HR, Arrighi HM, Bechten A, Morris K, McGovern M, Wattjes MP, AJNR Am J Neuroradiol 2013 34 1550 1555 10.3174/ajnr.A3475 23436056
20. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M, Bapineuzumab 201 Clinical Trial Investigators, Neurology 2009 73 2061 2070 10.1212/WNL. 0b013e3181c67808 19923550
21. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Lieberburg I, Arrighi HM, Morris KA, Lu Y, Liu E, Gregg KM, Brashear HR, Kinney GG, Black R, Grundman M, Lancet Neurol 2012 11 241 249 10.1016/S1474-4422(12)70015-7 22305802
22. A randomized, double-blind, placebo-controlled clinical trial of intravenous bapineuzumab in patients with Alzheimer's disease who are apolipoprotein E e4 non-carriers. Salloway S, Eur J Neurol 2012 19 C312
23. A randomized, double-blind, placebo-controlled clinical trial of intravenous bapineuzumab in patients with Alzheimer's disease who are apolipoprotein E e4 carriers. Sperling R, Eur J Neurol 2012 19 C3012
24. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, Friedrich S, Dean RA, Gonzales C, Sethuraman G, DeMattos RB, Mohs R, Paul SM, Siemers ER, Alzheimers Dement 2012 8 261 271 10.1016/j.jalz.2011.09.224 22672770
25. Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive? Tayeb HO, Murray ED, Price BH, Tarazi FI, Expert Opin Biol Ther 2013 13 1075 1084 10.1517/14712598.2013.789856 23574434
26. Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, Messer J, Oroszlan K, Rauchenberger R, Richter WF, Rothe C, Urban M, Bardroff M, Winter M, Nordstedt C, Loetscher H, J Alzheimers Dis 2012 28 49 69 21955818
27. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, Klunk WE, Ashford E, Yoo K, Xu ZX, Loetscher H, Santarelli L, Arch Neurol 2012 69 198 207 10.1001/archneurol.2011.1538 21987394
28. An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ Adolfsson O, Pihlgren M, Toni N, Varisco Y, Buccarello AL, Antoniello K, Lohmann S, Piorkowska K, Gafner V, Atwal JK, Maloney J, Chen M, Gogineni A, Weimer RM, Mortensen DL, Friesenhahn M, Ho C, Paul R, Pfeifer A, Muhs A, Watts RJ, J Neurosci 2012 32 9677 9689 10.1523/JNEUROSCI.4742-11.2012 22787053
29. Genentech's Alzheimer's antibody trial to study disease prevention. Garber K, Nat Biotechnol 2012 30 731 732 10.1038/nbt0812-731 22871696
30. A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study [ http://www.clinicaltrials.gov/ct2/ show/NCT01230853?term=ban2401&rank=2 ]
31. A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK933776) in Patients With Alzheimer's Disease [ http://www.clinicaltrials. gov/ct2/show/NCT00459550?term=GSK933776&rank=2 ]
32. Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease [ http://www.clinicaltrials.gov/ct2/show/NCT01193608?term= aab003&rank=1 ]
33. Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients [ http://www.clinicaltrials.gov/ct2/show/NCT01485302?term=SAR228810&rank=1 ]
34. Single Ascending Dose Study of BIIB037 in Subjects With Alzheimer's Disease [ http://www.clinicaltrials.gov/ct2/show/NCT01397539?term= BIIB037&rank=2 ] 19523013
35. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez Martinez de Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M, Lancet Neurol 2010 9 363 372 10.1016/S1474-4422(10)70043-0 20189881
36. Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient. Roher AE, Maarouf CL, Daugs ID, Kokjohn TA, Hunter JM, Sabbagh MN, Beach TG, J Alzheimers Dis 2011 24 315 325 21263194
37. Gantenerumab for the treatment of Alzheimer's disease. Delrieu J, Ousset PJ, Vellas B, Expert Opin Biol Ther 2012 12 1077 1086 10.1517/14712598.2012. 688022 22583155
38. Alzheimer's drugs take a new tack. Callaway E, Nature 2012 489 13 14 10.1038/489013a 22962697
39. Alzheimer's research. Stopping Alzheimer's before it starts. Miller G, Science 2012 337 790 792 10.1126/science.337.6096.790 22903991